Mouse Anti-MAPK4 (AA 42-151) Recombinant Antibody (CBFYM-1626) (CBMAB-M1793-FY)

Ren, J., Zheng, S., Zhang, L., Liu, J., Cao, H., Wu, S., ... & Sun, J. (2023). MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway. Cancer Medicine.

Han, D., Wang, W., Jeon, J. H., Shen, T., Huang, X., Yi, P., ... & Yang, F. (2023). Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy. PLoS biology, 21(8), e3002227.

Wang, W., Han, D., Cai, Q., Shen, T., Dong, B., Lewis, M. T., ... & Yang, F. (2022). MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nature communications, 13(1), 245.

Zeng, X., Jiang, S., Ruan, S., Guo, Z., Guo, J., Liu, M., ... & Dong, J. (2021). MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. Molecular medicine reports, 24(2), 1-8.

Shen, T., Wang, W., Zhou, W., Coleman, I., Cai, Q., Dong, B., ... & Yang, F. (2021). MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. The Journal of clinical investigation, 131(4).

Tian, S., Lou, L., Tian, M., Lu, G., Tian, J., & Chen, X. (2020). MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. Journal of Experimental & Clinical Cancer Research, 39(1), 1-11.

He, J., Huang, Z., He, M., Liao, J., Zhang, Q., Wang, S., ... & Liu, A. (2020). Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling pathway by sponging miR-125a-3p in gliomas. Molecular cancer, 19(1), 1-17.

Feng, Y., Zhang, L., Wu, J., Khadka, B., Fang, Z., Gu, J., ... & Liu, J. (2019). CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway. Journal of Experimental & Clinical Cancer Research, 38(1), 1-17.

Wang, W., Shen, T., Dong, B., Creighton, C. J., Meng, Y., Zhou, W., ... & Yang, F. (2019). MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. The Journal of clinical investigation, 129(3), 1015-1029.

Raj, S., Sasidharan, S., Dubey, V. K., & Saudagar, P. (2019). Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation. PloS one, 14(8), e0221331.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols